Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).
Psoriasis (PsO) is a chronic, systemic immune-mediated inflammatory disease that is associated with significant cardiovascular (CV)comorbidities.1,2 Recently, MIMS Doctor spoke to Dr Norazirah Md Nor, a Consultant Dermatologist at KPJ Ampang Puteri Specialist Hospital to gather her thoughts on the impact of early treatment on disease prognosis, and to understand the link between the severity of PsO and the risk of CV diseases (CVDs). Here are the highlights from the interview.
A group of paediatricians came together in a virtual satellite symposium held during the joint 11th Asia Pacific Paediatric Endocrine Society Biennial Scientific Meeting and the 42nd Annual Congress of the Malaysian Paediatric Association. The educational event, which was supported by GSK, served as a platform for the experts to review updates on paediatric respiratory diseases and discuss the importance of timely childhood immunisation.
In his welcome speech, Datuk Dr Zulkifli Ismail highlighted the inclusion of two new vaccines in Malaysia’s National Immunisation Programme (NIP) and its impact on local vaccination practices. Subsequently, Dr Asiah Kassim delivered a presentation on the importance of paediatric pneumococcal vaccines in preventing childhood respiratory infections, followed by a second lecture from Dato’ Dr Musa Mohd Nordin on optimising immunisation for children based on current data surrounding hexavalent combination vaccines.
Urogenital infections, particularly bacterial vaginosis and urinary tract infections (UTI), are common in women of reproductive age. Although these infections can be treated with antibiotic therapy, the global antibiotic resistance crisis has resulted in the emergence of multidrug resistant bacteria, with over seven million deaths caused by antibiotic-resistant bacteria each year. New antimicrobials eventually lose their efficacy owing to a multitude of factors that result in acquired resistance, including poor adherence to therapy. Thus, new treatment modalities are required to reduce the reliance on antibiotic use. One approach is the application of probiotics as a means of prophylaxis or antibiotic adjuvant therapy. Probiotic microorganisms are symbiotic in human hosts and, when consumed in adequate amounts, can provide health benefits, including antimicrobial effects and modulation of biological functions.
Dengue remains a public health issue in Malaysia despite years of public health efforts to mitigate the endemic disease. In this introductory part of the second interview of a series focused on dengue, Dr Ravindran Thayan, Head of Virology Unit at Institute for Medical Research, discussed progressive developments in dengue epidemiology in Malaysia over the last few decades.
Early identification and referral of patients with inflammatory back pain (IBP) to rheumatologists for further assessment is imperative in ensuring those with axial spondyloarthritis (axSpA) receive timely intervention. In this interview, Associate Professor Dr Fariz Yahya shared his insights into the development, use and importance of the primary care physician-targeted IBP referral algorithm, which had been published in Malaysian Family Physician
Psoriasis (PsO) is a lifelong, systemic inflammatory disease associated with multiple comorbidities that extends beyond just the surface of the skin.1 Recently, MIMS Doctor spoke to Dr Bong Jan Ling, a Consultant Dermatologist at Sunway Medical Centre to gather her thoughts on the current treatment landscape of PsO, specifically the risk factors of developing psoriatic arthritis (PsA), a condition closely related to PsO, and how the coronavirus disease 2019 (COVID-19) pandemic may have impacted the management of PsO.
At the recent Malaysia MPN Expert Forum, Dr Harry Gill, Clinical Assistant Professor at the University of Hong Kong, presented a review of the current treatment landscape in myelofibrosis (MF), along with a detailed look at the optimization of Jakavi® (ruxolitinib), Novartis in MF management. The forum was organized in collaboration between Novartis and the Malaysian Society of Haematology (MSH).